Abstract

Adrenal antibodies,  Pem brolizumab, Endocrine tissue, Hyperglycemia

Keywords: It has been demonstrated that medications that block immune checkpoints hasten type 1 diabetes. We describe a case of abrupt severe diabetic ketoacidosis in a patient without a history of the disease who became sick after beginning Pembrolizumab anti-PD1 treatment. Key Words: Melanoma, diabetic ketoacidosis, Pembrolizumab, immune checkpoint inhibitors, and programmed cell death receptor Introduction Pembrolizumab is a monoclonal antibody that functions by inhibiting the inhibitory ligand of the receptor and is primarily utilised to treat advanced metastatic malignant melanoma as well as previously less sensitive tumour types [1]. Therapy a 48-year-old lady was presented to the emergency room with a history of developing breathing problems during the previous 24 hours but no prior personal history of diabetes. She began to feel dehydrated at this time. She did not mention any recent upper respiratory infections, flu-like symptoms, or abdominal pain. There was no history of diabetes in the family. She had just received a melanoma diagnosis and was weeks into her treatment regimen when she presented. She had already undergone one cycle of pembrolizumab treatment.